Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of the Safety and Efficacy of CD19-CAR-T Cells in Patients With Relapsed or Refractory Acute B-cell Lymphoblastic Leukemia (R/R B-ALL)

NCT03574168 is registered in ClinicalTrials.gov with Bioceltech Therapeutics, Ltd. as lead sponsor.

NCT NCT03574168
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03574168 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of the Safety and Efficacy of CD19-CAR-T Cells in Patients With Relapsed or Refractory Acute B-cell Lymphoblastic Leukemia (R/R B-ALL)
Lead sponsor
Bioceltech Therapeutics, Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
July 20, 2018
Completion date
December 31, 2019
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell acute lymphoblastic leukemia